Pomegra
Dutch biotech Anaheim Bio has closed an oversubscribed €40 million Series A led by Droia Ventures to take its CPPD drug ANA-1 into a Phase I trial in 2027.
Key Takeaways
- Anaheim Bio raised an oversubscribed €40M Series A on November 5, 2026, led by Droia Ventures.
- ANA-1, a small-molecule pyrophosphate inhibitor, targets CPPD and is slated to enter Phase I in 2027.
- The company was spun out of Alesta Therapeutics before BioMarin bought Alesta for $275M upfront.
Lead
Anaheim Bio, a Leiden-based biotech, launched on November 5, 2026 with a €40 million (about $44.6 million) Series A financing for ANA-1, a preclinical small molecule aimed at calcium pyrophosphate deposition disease (CPPD). Droia Ventures led the round. Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest and Thuja Capital also participated. The company did not disclose a valuation.
The money covers IND-enabling studies and the first-in-human trial, with runway into 2028. Anaheim describes the round as oversubscribed.
Who Is Behind Anaheim Bio?
Anaheim Bio is a spinout, and its investor list shows it. The company was formed from programs that Alesta Therapeutics moved into a separate entity before BioMarin acquired Alesta, and Alesta's earlier backers have carried their positions over.
BioMarin announced the Alesta purchase in August 2026 at $275 million upfront, with up to $215 million more in milestones, for a total of up to $490 million. The prize was ALE1, an oral treatment for the rare bone disease hypophosphatasia. Under the deal structure, all non-ALE1 assets went into the spinout and Alesta employees moved with them, so no Alesta staff joined BioMarin.
Ilan Ganot is chief executive. Matthias Van Woensel is chief scientific officer, Rick Dekker is chief financial officer, and Benit Maru is interim chief medical officer. Luc Dochez of Droia chairs the board, which also includes Dan Estes of Frazier, Janwillem Naesens of Droia, Laura Brass of Novartis Venture Fund and independent director John McHutchison.
What Is CPPD and Why Does It Lack a Treatment?
CPPD is a form of inflammatory arthritis caused by calcium pyrophosphate crystals accumulating in and around joints. It is estimated to affect 4% to 7% of adults in Europe and the United States, which makes it far more common than most conditions that attract rare-disease financing.
Current therapies control inflammation and symptoms. No approved drug removes or dissolves the underlying crystal deposits. Patients are managed with anti-inflammatory approaches during flares, and the disease is often grouped with gout as a crystal arthropathy, though gout has urate-lowering drugs and CPPD has no equivalent.
How Does ANA-1 Work?
ANA-1 is a small-molecule inhibitor designed to lower extracellular pyrophosphate (PPi) levels, the raw material for calcium pyrophosphate crystals. The logic is to reduce crystal formation at its source rather than damp the inflammatory response after the fact.
The approach remains preclinical. Lowering pyrophosphate systemically carries a known biological trade-off, since the molecule also helps restrain mineralization in healthy tissue. How far ANA-1 can reduce PPi in joints without disturbing bone and vascular biology is the question the IND-enabling work and Phase I must begin to answer.
What Does This Round Say About Investor Appetite?
A €40 million Series A is mid-sized for European biotech, and the oversubscription claim fits a round assembled largely from existing holders. The investor base is the same group that backed Alesta, which just produced a $275 million upfront exit. That track record makes a follow-on cheaper to organize than a cold raise, and it also means the round is partly a vote on the team and the shared pyrophosphate biology rather than on clinical data, of which ANA-1 has none.
Specialist funds are present. RTW and Frazier are both established in crossover and venture-stage life sciences, and Novartis Venture Fund brings a pharma-linked balance sheet. The absence of a disclosed valuation limits how much can be read into pricing.
What Comes Next for Anaheim Bio?
The near-term milestones are IND-enabling toxicology and manufacturing work, followed by a Phase I start in 2027. With runway into 2028, the company has roughly one clinical readout window before needing new capital. A Phase I in healthy volunteers can show PPi reduction as a pharmacodynamic marker, but proof that crystal burden falls in patients would require longer Phase II studies the current round does not fund.
Large prevalence figures can also overstate the commercial case. Diagnosis rates for CPPD are low, and patient identification and trial endpoints for crystal dissolution are not standardized. Anaheim will need to define a measurable clinical outcome that regulators accept.
Outlook
Anaheim Bio enters 2027 with €40 million, a known investor syndicate and a mechanism aimed at an unmet need in a common joint disease. The value case rests on whether lowering extracellular pyrophosphate can shrink crystal deposits safely, and nothing in humans yet speaks to that. Phase I data, expected after the 2027 trial start, will be the first test, with a Series B decision likely to follow before the 2028 runway ends.
